tpan.com Quick Links

2004 HIV Drug Guide

2004 HIV Services Directory

Positively Aware

Positively Aware en Español

The continent of Africa has 29 of the world’s 42 million people living with HIV/AIDS. Most of them live in sub-Saharan Africa, by themselves making up 70% of the world’s total numbers. Today the scientists and medical providers of the wealthy nations race to Africa to fight the epidemic where it is hurting the most. There are not only lives to save and infections to prevent, but also medical knowledge to be gained. Political leaders and activists try to explain that the crisis of one country will affect other nations.

Dealing with AIDS in poor countries, however, is not a matter of simply giving out free drugs. To turn the pandemic around, several problems must be faced and resolved.

At the International AIDS Society meeting in Paris this past summer, Dr. Ernest Darkoh of Botswana highlighted some of the many issues that need to be addressed to effectively curb the epidemic in resource-poor countries. He put political will at the top.

Dr. Ernest Darkoh

“[HIV therapy] works—let’s not debate that but provide models for treatment,” Dr. Darkoh said. Most probably he was making a reference to the government of South Africa, which has stymied HIV care in every way possible, including turning down funds and free medicines. “History will remember us for how we act in this moment,” he went on. “If we do not act then we become the true enemy.”

Dr. Darkoh was eloquent, but also forthright, in his plenary talk, “Challenges and Lessons Learned in Implementing Antiretroviral Therapy in the Developing World.” The talk detailed the work of Botswana’s national HIV program, of which Dr. Darkoh is operations manager

.He did not hide the fact that one of the problems faced was with healthcare workers. Some of them did not want to work on HIV/AIDS and created stumbling blocks rather than promoting the government’s new efforts. Many were simply uncomfortable discussing HIV.

This then became a matter of education and guidance—another problem to resolve. Dr. Darkoh said that one obstinate worker could put efforts months behind, and HIV programs must continuously look for people who are a hindrance.

But the greater problem is simply staff training and fast-track recruitment. Then there’s the need for laboratory and clinical facilities. As he said, “Capacity is not something you achieve instantly. HIV/AIDS did not create the restraints we’re facing. They were there a long time ago.” The information and education needs alone were “massive,” he said.

In Botswana, the government determined that 300,000 people have HIV and roughly a third of them needed antivirals “immediately.” However, it could only provide medications right away to 10,000 people. People with less than 200 T-cells or an AIDS-defining illness were immediately eligible for antivirals, but the national program recognizes that all people with HIV need health monitoring. They also need pyscho-social support and wellness care.

“People were coming to us late, with an average of 50 to 60 CD4 cells. Sickness made them overcome stigma,” he said. This was one challenge: people who do not come forward for health care until they are very ill will then need many resources. The lesson is to encourage routine testing. Botswana conducts an educational campaign to combat stigma and get people to know their status.

It also distributes posters to help people with HIV understand the infection: that medication must be taken correctly, that therapy can help make people healthy but is not a cure, that condoms still need to be used.

Dr. Darkoh called many of the different challenges “sliding bottlenecks.” The question of political leadership was “quite a challenge in itself.” Then there are macroeconomic factors: “Most countries couldn’t tell you how many people need therapy or where to find them. You spend lots of time here in the heat of the epidemic.”

Not all of the work needs to be high-tech. “It could be, but could be someone on a bike, like the initiative in China,” he said. Adherence is promoted with a buddy system, along with pill counting and intensive counseling. And, as almost everywhere, there are experts from other countries helping to build Botswana’s program. Dr. Darkoh himself is from the United States, born to Ghanaian parents, who earned a medical degree and a Master’s in Public Health from Harvard University and an MBA from Oxford. He was recently profiled in the Christian Science Monitor in a story on Africans and people of African descent returning to help the continent.

According to the article, published September 30, “In Botswana, 38 percent of adults are HIV positive and life expectancy has plummeted to below 40 from over 65. By 2010, [life expectancy] could sink to 29, predicts the United Nations Program on HIV/AIDS—a level not seen in developed nations since the Middle Ages.”

To help Africa

Speaking before the annual meeting of the Midwest AIDS Training and Education Partners (MATEP) in Chicago in September, African American doctor Eric Goosby said, “I have a plea to all of the HIV healthcare providers here. I want you to put in your head that you can make an extraordinary contribution by coming in to these countries for six weeks. Working directly with healthcare providers in Africa would provide the best training possible for them,” he said.

Dr. Goosby is CEO for the Pangea Global AIDS Foundation, located in San Francisco. He was director of HIV/AIDS Policy for the U.S. Department of Health and Human Services under the Clinton administration. Dr. Goosby directed people to visit Pangea’s website at www.pgaf.org for information on how to contribute your service. He said healthcare providers can also recruit patients with home care service information to impart.

Lessons from Botswana

  • Capacity-building is not linear.
  • Each site experiences teething problems and can later help the sites coming after them.
  • Public/private partnerships should be encouraged (the Botswana government works with the Bill & Melinda Gates and the Merck Company foundations, each pledging $50 million a year for five years).
  • HIV should be a national priority, not necessarily an individual priority—public motivation and mobilization are critical.
  • Low knowledge of HIV status severely limits the ability to plan rapidly.
  • ARV [antivirals] helps break cycles of denial and strongly facilitates prevention.
  • Developed countries must take a leadership role.
  • Individuals must take responsibility and come forward for care sooner in the course of their disease.
  • Private companies have something to offer way beyond money—management skills and marketing knowledge.
  • HIV/AIDS must be looked at in the context of the total healthcare delivery system.

| Positively Aware | 2004 HIV Drug Guide | Positively Aware en español |

|Chicago Area HIV Services Directory | Publications Home |

| Publications | Client Services | MOCHA | Events | Helping TPAN |

| Contacts and Staff | About TPAN | Ask TPAN | Links | TPAN Home |